| Developers: | Roche |
| Date of the premiere of the system: | June, 2018 |
| Branches: | Pharmaceutics, medicine, health care |
2018: Announcement of the first-ever coagulometer Bluetooth-enabled
On June 11, 2018 the Roche company announced the beginning of sales of the new automatic CoaguChek Vantus coagulometer. As the producer says, it is the first-ever device for independent control of coagulability of blood with the built-in support of technology of wireless communication of Bluetooth.
Equipped with the color display, the CoaguChek Vantus coagulometer in appearance reminds the old-fashioned mobile phone. The device can be shared with the smartphone or the tablet. Using Bluetooth results of measurements of an indicator of coagulability of MNO blood automatically go to customized mobile application on the smartphone or the patient's tablet, from there data are transferred to the medical organization.
CoaguChek Vantus provides the new level of monitoring of a status of the patients who are on therapy varfariny, saves patients from need to send measurements manually or to spend time for phone calls in hospital and also reduces number of visits to clinics and laboratories for taking of analyses.
| The problem of increase in availability of medical services and cutting of costs for their rendering is always relevant for a health care system. In this context ensuring the improved communication between suppliers of medical services and patients purchases a bigger value. This advanced technology sets the new standard of monitoring of coagulability of blood, providing high quality and convenience when sampling and also optimizing process of the reporting on analysis results of the patient, - doctor Alan Wright, the chief medical employee of Roche Diagnostics said.[1] |
Among other features of the new coagulometer in Roche noted convenience and simplicity of the electronic menu of the device and an opportunity to program regular reminders on need of measurement of MNO.
Receipt of CoaguChek Vantus in sale in the USA is planned for July, 2018. Availability and date of an exit in other markets it is not announced yet.[2]

